Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to tackle tough breast cancer

NCT ID NCT06942234

Recruiting now Disease control Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new drug called JSKN016, given with chemotherapy or immunotherapy, for people with HER2-negative breast cancer that cannot be removed by surgery or has spread. The trial includes 180 adults in China and aims to see if the combination shrinks tumors and how safe it is. It is an early-stage study, so results are not yet known.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
JSKN016 (a drug given by IV) combined with chemotherapy (capecitabine or paclitaxel) or immunotherapy
What this could lead to
If successful, this could offer a new treatment option for people with advanced HER2-negative breast cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the treatment may not prove effective or safe enough for wider use. Side effects from the drug combinations are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INOPERABLE LOCALLY ADVANCED HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Her2-receptor negative breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INOPERABLE LOCALLY ADVANCED HER2-NEGATIVE BREAST CANCER METASTATIC HER2-NEGATIVE BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer center

    RECRUITING

    Shanghai, China

    Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.